NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Novartis back to previous page show list

Novartis

»
address: Novartis Pharmaceuticals UK Ltd
Frimley Business Park
Frimley
Camberley
Surrey GU16 7SR
contact:
key person: CEO Daniel Vasella

trunover in millions USD: 38100
R & D turnover in millions USD: 6400
NET profit: 6
year of financial results: 2007
employees: 92

active in China: YES
partner in China: Novartis Institute for BioMedical Research (NIBR)
ZhangJiang Science Park
Shanghai

SFDA approved: NO

Approvals:
GLP: NO
GMP: NO
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
R&D: YES
Ingredients: YES
Western Generics: YES
TCM: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: YES
Batch Release: YES

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: YES

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 

Created in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis is currently organized into four divisions.

The Novartis Pharmaceuticals Division is a world leader in the discovery, development, manufacture, and marketing of prescription medicine. Their goal is to provide a broad portfolio of innovative, effective and safe products and services to patients through healthcare professionals around the world.

In 2006, the Pharmaceutical's business posted sales of USD 22.6 billion. Their current product portfolio includes more than 40 key marketed products, many of which are leaders in their respective therapeutic areas. The Development portfolio involves over 130 projects - including potential new products as well as potential new indications or formulations for existing products - in various stages of clinical development.

The Pharmaceutical Division consists of the following therapeutic areas:

General Medicines;Cardiovascular & Metabolism;Neuroscience;Respiratory & Dermatology;ABGHIInfectious diseases;

An emerging area of therapeutic focus is infectious diseases, particularly products used to treat viral infections by inhibiting their replication.their portfolio consists of three main areas: anti-virals, anti-bacterials and tropical medicine. They market Famvir for herpes and Coartem/Riamet for malaria. Ongoing research and development efforts are focused on new specific anti-virals against Hepatitis B and C, as well as on novel antibiotics for respiratory tract infections.

They established Infectious Diseases as a separate franchise following our May 2003 purchase of a majority of the outstanding capital stock of Idenix Pharmaceuticals, Inc. As a result of that transaction, they obtained certain rights to market Idenix products, as well as options to license additional Idenix compounds in the future. (Arthritis, bone, gastrointestinal, hormone replacement therapies, urinary incontinence): The primary focus of this therapeutic area is a group of treatments for patients with a variety of internal diseases that have significant unmet medical needs, particularly in the areas of gastrointestinal disorders, urinary incontinence, arthritis, osteoporosis and the treatment of pain.

They have entered the gastrointestinal market with the launch of Zelnorm/Zelmac for the treatment of irritable bowel syndrome (IBS), a condition where the bowel (large intestine) does not function properly. More than 40 million Americans are estimated to suffer from IBS with constipation, and Zelnorm/Zelmac is the first and only medication approved to treat this condition. Zelnorm/Zelmac is also approved for the treatment of chronic idiopathic constipation in the US and several other countries.

They intend to further strengthen our GI franchise with development efforts for Zelnorm/Zelmac in other indications. Another important area of focus are bone disorders like osteoporosis, a progressive disease that causes bones to become thin and porous, increasing the risk for fractures. The most advanced compound in development for bone disorders is Aclasta, which was submitted in the US for Paget’s disease in 2004 and is in development for osteoporosis. Novartis offers a series of leading medicines for important respiratory and dermatological conditions Elidel is the first and only non-steroid cream for eczema, an inflamed skin condition that affects about 10% of children in the US, while Lamisil is the most frequently prescribed treatment worldwide for fungal nail infection. The long-acting bronchodilator Foradil for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Novartis has been a leader in neuroscience for more than 50 years, having pioneered early breakthrough treatments for disorders that include Alzheimer’s disease, Parkinson’s disease, attention deficit / hyperactivity disorder, epilepsy, depression, migraine and schizophrenia. Among our leading products are the anti-epileptic Trileptal, which has been approved in more than 70 countries and used to treat over one million people suffering from epilepsy, and Exelon, which is used for the treatment of mild to moderate Alzheimer’s disease. Novartis continues to be active in developing new compounds and is committed to addressing unmet medical needs, as well as supporting patients and their families affected by these disorders. Ongoing research to extend the current product portfolio in Neuroscience includes projects in psychiatric diseases, neurological disorders and chronic pain.

Specialty Medicines:

Oncology & Hematology:Transplantation & Immunology:Ophthalmics;

They develop and market products for the treatment of a number of different ophthalmic diseases. Their research and development in this disease area is aimed at the discovery and development of innovative treatments for "Back of the Eye" diseases as well as on "Dry Eye" Conditions. Both of these areas are characterized by high growth and significant unmet medical needs. The "Back of the Eye" area encompasses several disease areas, such as wet and dry age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema and retinitis pigmentosa. The key area of focus within "Back of the Eye" is "wet" AMD, a condition when leaky blood vessels grow across the central portion of the retina, or macula for unknown reasons and cause bleeding, scar formation and permanent damage, leading to vision loss.

Their Ophthalmics business has built a leadership position with its flagship product Visudyne. In cooperation with collaborator Genentech, we are also developing Lucentis, a VEGF inhibitor that is currently in Phase III clinical trials for the treatment of "wet" AMD and will be marketed by Novartis outside of North America.

Novartis is a world leader in transplantation and immunology, pioneering and revolutionizing the field of transplantation with the discovery and introduction of cyclosporine more than 20 years ago. We have one of the broadest portfolios of immunosuppressants due to our continued research and strong commitment to provide solutions to unmet medical needs for the transplant recipient. Neoral and Simulect are established products used to protect transplanted organs from rejection. Our new products Certican and myfortic, which has now been approved in more than 40 countries, are providing more choices to transplant physicians. A novel immunomodulating agent, FTY720, is currently in Phase III for use in transplantation, and patient enrollment was completed in September 2004. With a worldwide research program, Transplantation & Immunology is committed to developing a new and innovative range of therapeutic products for the prophylaxis of organ rejection and to maintain our role as global leader in this field.Pharmaceuticals (Frimley) R & D Pharmaceutical Operations (Horsham) 

Vaccines and Diagnostics 

Sandoz Generics

Consumer Health

Novartis in China

NIBR (Novartis Institute for Biomedical Research - Shanghai)  is the company's R & D Centre in China focussing on prevalent diseases in China and Asia in particular: infectuous causes of

Up to now, with a total investment of more than USD100 million in China, Novartis has 5 enterprises in China covering the fields of pharmaceuticals, consumer health, eye-care and animal health, and employs about 1,700 people in mainland China.
The total revenues of Novartis in China reaches RMB 1.56 billion in 2004, an increase of 36.3% year on year, including increase in these two main business operations: Innovative Medicines 39.1% and Consumer Health 15.5%. 
  •  Novartis Country Organization (Beijing) –Regional Headquarter In China
  •  Beijing Novartis  Pharma Co. Ltd.
  •  Shanghai Ciba Vision Contact Lenses Co. Ltd.;
  •  Shanghai Novartis Nutrition Ltd.;
  •  Shanghai Novartis Animal Health Co. Ltd.;
  •  Novartis (Jiangsu) Agrochemicals Co. Ltd.; Hong Kong Novartis Agro (China) Ltd.;
  •  Shouguang Novartis Seeds Ltd.(Shandong)

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.